Albert David Ltd

Albert David Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Albert David Ltd’s share price declined sharply to a new 52-week low of Rs.645 on 9 March 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical company’s shares have underperformed both the sector and broader market indices, reflecting persistent challenges in financial performance and market sentiment.

Albert David Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 February 2026, providing investors with an up-to-date view of its performance and outlook.

Albert David Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Albert David Ltd., a Kolkata-based pharmaceutical manufacturer, reported a net loss of ₹3.30 crores in Q2 FY26 (Jul-Sep'25), marking a sharp reversal from the ₹18.07 crores profit posted in the same quarter last year—a staggering decline of 118.27% year-on-year. The loss comes despite a modest sequential recovery in the previous quarter, highlighting persistent operational challenges that have plagued the company throughout FY25 and into FY26.

Albert David Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 14 May 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below represent the company’s current position as of 05 February 2026, providing investors with the latest insights into its performance and prospects.

Albert David Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low, closing just 0.67% above its lowest price of Rs 684.4. This marks a significant milestone in the stock’s ongoing downward trajectory, reflecting persistent financial difficulties and subdued market performance over the past year.

Albert David Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 14 May 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 25 January 2026, providing investors with the latest insights into its performance and prospects.

Albert David Ltd, a player in the Pharmaceuticals & Biotechnology sector, recorded a fresh 52-week low of Rs.686.45 today, marking a significant decline amid a sustained downward trend over recent sessions.

Albert David Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.705 today, marking a significant decline in its stock price amid ongoing downward momentum and underperformance relative to its sector and broader market indices.

Albert David Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 May 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 14 January 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall market standing.

Albert David Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 May 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 03 January 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Albert David Ltd’s shares declined to a fresh 52-week low of Rs.730.05 on 30 Dec 2025, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical and biotechnology company’s stock has underperformed its sector and broader market indices, reflecting persistent pressures on its financial performance and valuation metrics.

Albert David, a player in the Pharmaceuticals & Biotechnology sector, touched a new 52-week low of Rs.738.95 today, marking a significant milestone in its ongoing price decline. This level reflects a continuation of the stock’s subdued performance over the past year, contrasting sharply with broader market trends.

Albert David, a microcap player in the Pharmaceuticals & Biotechnology sector, has undergone a revision in its market evaluation reflecting ongoing challenges in its financial and technical outlook. The recent assessment highlights shifts across key analytical parameters, signalling caution for investors amid subdued returns and operational pressures.

Albert David's shares reached a fresh 52-week low of Rs.740.25 today, marking a significant decline amid a sustained downward trend over recent sessions. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology industry.

Albert David, a company in the Pharmaceuticals & Biotechnology sector, recorded a new 52-week low of Rs.754.55 today, reflecting a continuation of its downward trajectory over the past year. The stock's performance contrasts sharply with broader market trends, underscoring ongoing challenges within the company’s financial results and market positioning.